Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-567 is a microRNA that functions as a tumor suppressor in melanoma. Research indicates that miR-567 expression is significantly reduced in melanoma tissues compared to benign nevi, and its downregulation is associated with poorer patient survival. As a therapeutic candidate, miR-567 acts by directly targeting and silencing the mRNA of key oncogenic drivers, including Insulin-like Growth Factor 1 Receptor (IGF1R), E2F Transcription Factor 1 (E2F1), and Cyclin B2 (CCNB2). This multi-targeted inhibition results in the suppression of the MAPK/ERK and PI3K/AKT signaling pathways, leading to reduced tumor cell proliferation, migration, and invasion, even in BRAF-inhibitor resistant cells. Furthermore, miR-567 has been shown to modulate the tumor microenvironment by inhibiting the growth-promoting effects of M2-polarized and melanoma-associated macrophages (MAMs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-567.